INTRODUCTION AND OBJECTIVES: MRI-guided transurethral ultrasound ablation (TULSA) is a novel minimally-invasive procedure for customized prostate ablation. We report one-year outcomes from the TULSA-PRO Ablation Clinical Trial (TACT).
METHODS: The study enrolled 115 men with organ-confined prostate cancer ( T2b, PSA 15 ng/ml, Gleason Grade Group 1-2) across 13 centers in USA, Europe, and Canada. Treatment intent was whole-gland ablation with sparing of the urethra and urinary sphincter. The primary safety endpoint was frequency and severity of adverse events (CTCAE). The primary efficacy endpoint was proportion of men achieving a PSA reduction ! 75%. Secondary endpoints included one-year 10-core biopsy, prostate volume reduction, and quality of life (IPSS, EPIC) .
RESULTS: Median (IQR) age was 65 (59-69) years and PSA 6.3 (4.6-7.9) ng/ml. Pre-treatment, 72 of 115 (63%) men had Grade Group 2 (GG2) and 77 (67%) had NCCN intermediate-risk disease. Median (IQR) treatment delivery time was 51 (39-66) min for targeted prostate volumes of 40 (32-50) cc with 98% (95-99%) thermal coverage of target volume and spatial ablation precision of AE1.4 mm on MRI thermometry. Grade 3 adverse events occurred in 9 (8%) men, including infections (4%), urethral stricture (2%), urinary retention (2%), urethral calculus and pain (1%), and urinoma (1%), all resolved. There were no rectal injuries or Grade ! 4 events. The primary endpoint of PSA reduction !75% was achieved in 110 of 115 (96%), with median (IQR) PSA reduction of 95% (91-98%) and nadir of 0.34 (0.12-0.56) ng/ml. Median perfused prostate volume decreased from 41 to 4 cc. Among 68 men with pre-treatment intermediate-risk GG2, 52 (79%) were free of GG2 disease on one-year biopsy. Of 111 men with one-year biopsy data, 72 (65%) had no evidence of any cancer. Of 112 men with one-year continence data, 1% were incontinent (>1 pad/day), daily leakage increased 4%, and 8% wore a pad. Median IPSS was unchanged at one year, from 6 to 6 (n[105). At one year, 20% of patients had Grade 2 erectile dysfunction, median (IQR) change in IIEF-5 was -3 (-13 to 0, n[105), and 69 of 92 (75%) maintained erections sufficient for penetration (IIEF Q2 ! 2). Multivariate predictors of GG2 at one year included presence of intraprostatic calcifications at screening, MRI thermal coverage of target volume, and PIRADS ! 3 lesion at one-year post-treatment MRI (p < 0.05).
CONCLUSIONS: The TACT pivotal study of MRI-guided transurethral ultrasound whole-gland ablation (TULSA) in men with localized prostate cancer met its primary endpoint of !75% PSA reduction in 96% of patients with low rates of severe toxicity and residual GG2 disease. 
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INTRODUCTION AND OBJECTIVES:
Many transplant centres utilize a hard cut off of 2 hours of warm ischemic time (WIT), defined as the time from withdrawal of life-sustaining measures to cold organ flush, to exclude donation after circulatory determination of death (DCD) kidney donation. As a result, 30% of withdrawals to retrieve DCD organs fail to produce kidney transplants in Ontario. In order to assess our ability to increase organ yield, we wanted to characterize WIT, and functional WIT (fWIT, time from systolic blood pressure <50 mmHg to cold organ flush), as well as determine the time at which potential donors eventually die in those that did not become organ donors.
METHODS: A retrospective review of all DCD kidney donors in Ontario was performed utilizing the Trillium Gift of Life Database from April 2013 to April 2018 in order to determine: 1. The WIT of all DCD kidney donors in Ontario; 2. The percentage of DCD kidney donors that have a 30 minute fWIT; and 3. The time in which potential donors eventually die in those that did not become organ donors.
RESULTS: Of 350 DCD kidney donors analyzed, 46.9% had <0.5 hours, 51.7% between 0.5 -2 hours and 1.4% >2 hours of WIT. In each of these categories (WIT <0.5h, 0.5 -2 hours and >2 hours), the percentage of patients with fWIT <30min were 100%, 94.4% and 100% respectively (p [ NS). There were 106 potential donors who did not end up donating due to WIT >2 hours. Of these, 20.8% died between 2-4 hours, 10.4% between 4 -6 hours and 68.8% beyond 6 hours.
CONCLUSIONS: The percentage of donors with fWIT > 30 min did not increase with increasing WIT in DCD donors that went on to donate organs. These data support assessment of waiting up to 4 hours for DCD kidney donation as long as fWIT remains low given the shortage of available organ donors.
